Evidence map›Paper›PMID 35750288›Full record

ArticleNew biotechnology2022

Derivation of splice junction-specific antibodies using a unique hapten targeting strategy and directed evolution.

Emily P Fuller, Rachel J O'Neill, Michael P Weiner

Open access · goldAbstract read
In one paragraph

Article in New biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Epivolve: A Protocol for Site-Directed Antibodies.Methods in molecular biology (Clifton, N.J.) · 2023
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Emily P FullerInstitute for Systems Genomics, University of Connecticut, Storrs, CT 06269, USA; Department of Molecular and Cell Biology, University of Connecticut, Storrs, CT 06269, USA; Abcam, 688 East Main Street, Branford, CT 06405, USA.
Rachel J O'NeillInstitute for Systems Genomics, University of Connecticut, Storrs, CT 06269, USA; Department of Molecular and Cell Biology, University of Connecticut, Storrs, CT 06269, USA. Electronic address: rachel.oneill@uconn.edu.
Michael P WeinerAbcam, 688 East Main Street, Branford, CT 06405, USA. Electronic address: rachel.oneill@uconn.edu.
University of Connecticut · USAbcam (United States) · US

Funding

Development and Utilization of Splice-specific AntibodiesR21CA240199 · NCI · UNIVERSITY OF CONNECTICUT STORRS · PI O'NEILL, RACHEL · 2019 to 2021
$549k
NCI NIH HHS R21 CA240199
6 · The paper itself

Abstract

Alternative splicing of RNA occurs frequently in eukaryotic cells and can result in multiple protein isoforms that are nearly identical in amino acid sequence, but have unique biological roles. Moreover, the relative abundance of these unique isoforms can be correlative with diseased states and potentially used as biomarkers or therapeutic targets. However, due to high sequence similarities among isoforms, current proteomic methods are incapable of differentiating native protein isoforms derived from most alternative splicing events. Herein, a strategy employing a nonsynonymous, non-native amino acid (nnAA) pseudo-hapten (i.e. an amino acid or amino acid derivative that is different from the native amino acid at a particular position) as a targeting epitope in splice junction-spanning peptides was successful in directed antibody derivation. After isolating nnAA-specific antibodies, directed evolution reduced the antibody's binding dependence on the nnAA pseudo-hapten and improved binding to the native splice junction epitope. The resulting antibodies demonstrated codependent binding affinity to each exon of the splice junction and thus are splice junction- and isoform-specific. Furthermore, epitope scanning demonstrated that positioning of the nnAA pseudo-hapten within a peptide antigen can be exploited to predetermine the isolated antibody's specificity at, or near, amino acid resolution. Thus, this nnAA targeting strategy has the potential to robustly derive splice junction- and site-specific antibodies that can be used in a wide variety of research endeavors to unambiguously differentiate native protein isoforms.

Indexed as

Alternative SplicingProteomicsAmino AcidsEpitopesHaptensPeptidesProtein IsoformsAmino AcidsEpitopesHaptensPeptidesProtein IsoformsAlternative splicingAntibodyDirected evolutionHaptenIsoformSplice junction

Identifiers

PMID35750288
PMCPMC9464090
OpenAlexW4283266913

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.